Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer ; volume:9 ; number:1 ; day:2 ; month:11 ; year:2018 ; pages:1-11 ; date:12.2018
Nature Communications ; 9, Heft 1 (2.11.2018), 1-11, 12.2018
- Urheber
-
Caetano, Mauricio S.
Hassane, Maya
Van, Hieu T.
Bugarin, Emmanuel
Cumpian, Amber M.
McDowell, Christina L.
Cavazos, Carolina Gonzalez
Zhang, Huiyuan
Deng, Shanshan
Diao, Lixia
Wang, Jing
Evans, Scott E.
Behrens, Carmen
Wistuba, Ignacio I.
Fuqua, Susan A. W.
Lin, Huang
Stabile, Laura P.
Watowich, Stephanie S.
Kadara, Humam
Moghaddam, Seyed Javad
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-018-07042-y
- URN
-
urn:nbn:de:101:1-2018121721334477993035
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Caetano, Mauricio S.
- Hassane, Maya
- Van, Hieu T.
- Bugarin, Emmanuel
- Cumpian, Amber M.
- McDowell, Christina L.
- Cavazos, Carolina Gonzalez
- Zhang, Huiyuan
- Deng, Shanshan
- Diao, Lixia
- Wang, Jing
- Evans, Scott E.
- Behrens, Carmen
- Wistuba, Ignacio I.
- Fuqua, Susan A. W.
- Lin, Huang
- Stabile, Laura P.
- Watowich, Stephanie S.
- Kadara, Humam
- Moghaddam, Seyed Javad
- SpringerLink (Online service)
Ähnliche Objekte (12)
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
K-Ras protein as a drug target
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers
Targeting ErbB receptors in a three-dimensional cell culture model of K-Ras mutant colorectal cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
K-Ras protein as a drug target
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers
Targeting ErbB receptors in a three-dimensional cell culture model of K-Ras mutant colorectal cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
K-Ras protein as a drug target
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers